HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer

Transl Lung Cancer Res. 2020 Oct;9(5):2178-2183. doi: 10.21037/tlcr-20-578.

Authors

Toshimitsu Yamaoka^{1

2}, Junji Tsurutani¹, Hironori Sagara², Tohru Ohmori²

Affiliations

¹ Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
² Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

No abstract available

Publication types

Editorial
Comment